Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02571192 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate How the Study Drug SHP626 is Eliminated From the Body After One Dose
A Phase 1 study, sponsored by Mirum Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT02571192 is a Phase 1 study that has completed, run by Mirum Pharmaceuticals. The registered enrollment target is 8 participants.
The verdict
NCT02571192, a Phase 1 study, has completed, sponsored by Mirum Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to determine how SHP626 is absorbed and excreted from the body in healthy males.
Interventions
- DRUG SHP626
- RADIATION 5.95 μCi RAD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2015-10-01 |
| Est. Completion | 2015-10-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02571192
The ClinicalTrials.gov registry entry for NCT02571192 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mirum Pharmaceuticals, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which SHP626 is the first listed.
NCT02571192 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02571192 about?
NCT02571192 is a clinical study titled "A Study to Investigate How the Study Drug SHP626 is Eliminated From the Body After One Dose". The purpose of this study is to determine how SHP626 is absorbed and excreted from the body in healthy males.
What is the current status of trial NCT02571192?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2015-10-01. Estimated completion is 2015-10-01.
What interventions are being tested in trial NCT02571192?
The interventions under investigation include: SHP626 (DRUG), 5.95 μCi RAD (RADIATION).
Who is sponsoring clinical trial NCT02571192?
This trial is sponsored by Mirum Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.